Previous Close | 26.89 |
Open | 26.88 |
Bid | 26.66 x 2200 |
Ask | 26.98 x 2200 |
Day's Range | 26.87 - 26.90 |
52 Week Range | 7.67 - 27.02 |
Volume | |
Avg. Volume | 872,155 |
Market Cap | 2.614B |
Beta (5Y Monthly) | 2.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.22 |
Earnings Date | Jan 26, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for MYOV
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estima
Seely steps into the top operational roles at a company where outgoing president and CEO Liz Homans guided two cancer cell therapies into the clinic.